EGFR and non-small cell lung carcinoma: Initial targeted sequencing of the four patients revealed that all patients harbored MDM2 amplification, therefore, we hypothesized that MDM2 amplification may induce primary resistance to EGFR-TKIs and result in a poor prognosis of NSCLC patients harboring sensitive EGFR mutations.